# Danaher (DHR) Q3 2026 earnings

Results filed 2026-10-21 for the quarter ended 2026-09-25. Source page: https://earnings.opennash.com/companies/dhr/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/313616/000031361626000201/0000313616-26-000201-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Danaher's new CEO is shifting from reshaping the portfolio to connected selling and AI-driven science, launching an autonomous lab and partnering with NVIDIA to turn breadth into a growth edge.

Demand improved across Danaher's end markets. Bioprocessing orders grew mid-teens, led by upstream consumables and resins. Non-respiratory diagnostics grew 7%, helped by Beckman Coulter's strongest quarter in more than two years and Cepheid's non-respiratory tests. The company announced its first AI-powered autonomous lab, a partnership with NVIDIA, and work with Anthropic on instrument connectivity. Leica Biosystems closed its StatLab acquisition, and Masimo kept growing at a high single-digit pace.
New CEO Julie Sawyer Montgomery wants growth from the businesses Danaher already owns, built on four priorities: commercial excellence, innovation, talent and disciplined capital allocation. The aim is to sell more as one Danaher while keeping the operating companies' customer intimacy. The tension is execution: management says credibility will be earned through results. Reshoring and AI demand are still early, and AI is not yet material to sales.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $6.6 billion | up 8.5% year-over-year | GAAP |
| Net earnings | $1.2 billion | up 34.5% year-over-year | GAAP |
| Diluted EPS | $1.71 | up 34.5% year-over-year | GAAP |
| Adjusted diluted EPS | $2.11 | up 11.5% | non-GAAP |
| Gross margin | 58.5% |  | GAAP |
| Operating profit | $1,245 |  | GAAP |
| Adjusted operating profit margin | 29.0% | up 110 bps | non-GAAP |
| Operating cash flow | $1.9 billion |  | GAAP |
| Free cash flow | $1.6 billion | up approximately 19.0% | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Biotechnology sales | $1,807 | core sales up 5.0% |
| Life Sciences sales | $1,865 | core sales up 4.5% |
| Diagnostics sales | $2,882 | core sales up 0.5%; up 7.0% excluding respiratory |
| Core revenue growth excluding respiratory | 5.5% |  |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Core revenue growth excluding respiratory | fourth quarter 2026 | 4.0% to 5.0% |
| Adjusted operating profit margin | fourth quarter 2026 | approximately 29.5% |
| Adjusted diluted EPS | full year 2026 | $8.57 to $8.62 |
| Effective tax rate | year ending December 31, 2026 | ~17.0% |
| Core revenue growth excluding respiratory (starting point) | 2027 | 4 % to 5 % |

## Key takeaways

1. **Danaher launched an AI-powered autonomous lab** The lab combines AI, robotics and technologies from Cytiva, Beckman Coulter Life Sciences, Genedata, IDT and Molecular Devices in a design-make-test loop, which management says delivers up to eight times faster discovery of reagents. A new NVIDIA collaboration and work with Anthropic on instrument connectivity extend the AI strategy.
2. **New CEO pushes connected selling across operating companies** In diagnostics, bringing leaders from several businesses together in front of key customers has created several hundred millions of dollars of opportunity. Sawyer Montgomery wants to repeat this across all three platforms while keeping the operating company structure.
3. **Bioprocessing orders point to stronger 2027** Orders grew mid-teens, led by upstream consumables and resins, with equipment orders in a strong double-digit range. Reshoring is mostly a 2028-plus event, with greenfield projects still in planning.
4. **Masimo and StatLab broaden the diagnostics portfolio** Masimo posted high single-digit growth and won FDA clearance for a platform that can help detect atrial fibrillation. Leica Biosystems closed StatLab in early Q4 to build a fuller pathology workflow.
5. **Non-respiratory diagnostics strength is masked by flu weakness** Core growth excluding respiratory was 7%, with Beckman Coulter Diagnostics at its best in more than two years and Cepheid's non-respiratory business up low double digits. Respiratory is planned at about $1.5 billion for 2026 and as the starting point for 2027.

## Analyst Q&A

- [0:30:10] Doug Schinkle, UBS: How is the new CEO balancing Danaher's operational legacy against the need to change the playbook? Answer: She will keep the operating company structure, talent and business system, while becoming a more connected Danaher with unambiguous share gain as the report card.
- [0:34:27] Doug Schinkle, UBS: Which priority matters most over the next 12 to 18 months and what metrics should investors watch? Answer: Commercial excellence is the nearest-term priority, with higher profitable core growth and share gain as the measures.
- [0:37:13] Vijay Kumar, Evercore ISI: Should bioprocessing grow at very high single digits or low double digits in 2027? Answer: Orders support improving growth rates in 2027, but formal guidance waits until after Q4 planning, and the long-term view stays at high single digits.
- [0:40:40] Vijay Kumar, Evercore ISI: How does the CEO view M&A priorities and does Masimo signal a medtech tilt? Answer: M&A remains the capital allocation bias, but Masimo is seen as a continuous diagnostic that compounds with diagnostics, with no medtech bias.
- [0:42:39] Tycho Peterson, Jefferies: Why is 2027 core growth excluding respiratory only 4% to 5%, and is something being left out? Answer: It matches recent quarters and current market conditions, and a quantitative outlook will follow in January after Q4 planning.
- [0:43:38] Tycho Peterson, Jefferies: Why cut respiratory again, and is $1.5 billion the right base for 2027? Answer: Management plans for a typical flu season at $1.5 billion for 2026 and 2027, noting seasonal swings could move it by a couple hundred million dollars.
- [0:45:43] Jack Meehan, Seaport Research: How does the CEO view AI's implications for Danaher and its internal deployment? Answer: AI-driven drug discovery is a major long-term opportunity, with Danaher holding instruments, consumables, automation, software and scale, and AI is paired with DBS internally.
- [0:48:48] Jack Meehan, Seaport Research: What is the broader strategy behind the autonomous lab and the NVIDIA announcement? Answer: The goal is to connect AI to physical experiments, proving it inside Danaher first, then working with customers and with NVIDIA and Anthropic.
- [0:51:42] Scott Davis, Melius Research: What are the first steps to improve commercial execution, such as compensation or people changes? Answer: She is standardizing sales expectations through DBS and using AI for coaching, and incentives are protected so connected selling never hurts anyone's pay.
- [0:54:15] Scott Davis, Melius Research: How will M&A processes change to raise hit rates without freezing deal-making? Answer: Danaher will keep doing deals but focus on strategically compounding M&A with robust returns, having learned from past misses.
- [0:56:15] Casey Woodring, JPMorgan: How is Masimo trending and how should we think about its contribution next year? Answer: Masimo grew high single digits in its first full quarter, integration is going well, and a healthy funnel of commercial synergies remains.
- [0:58:14] Casey Woodring, JPMorgan: What is behind bioprocessing equipment orders, and how will reshoring contribute in 2027? Answer: Equipment orders are in a strong double-digit range, while reshoring is mostly brownfield now, with greenfield impact mostly from 2028.
- [1:00:12] Evie Kozlowski, Goldman Sachs: Where are life sciences end markets in their recovery and where could upside come from? Answer: Pharma and biopharma are robust, biotech funding is reading through, academic is improving modestly from low levels, and early AI-driven workflow demand is showing in automation.

## Questions

**What are Danaher's strategic priorities under its new CEO?** Julie Sawyer Montgomery named four: commercial excellence, innovation, talent and effective capital allocation. The near-term focus is commercial execution and selling as a more connected Danaher.
**What is Danaher doing in AI?** It announced its first AI-powered autonomous lab, a collaboration with NVIDIA, and work with Anthropic on connecting instruments to agents. Management says AI is not yet material but is giving a modest benefit to orders and revenue.
**How is bioprocessing demand developing?** Orders grew mid-teens, led by upstream consumables and resins, with equipment orders in a strong double-digit range. Management expects growth to keep improving in 2027, with reshoring contributing mostly from 2028.
**Which acquisitions did Danaher highlight?** Leica Biosystems closed StatLab in early Q4 to complete a pathology workflow, and Masimo grew high single digits and received its sixth FDA clearance this year. Management calls both strategically compounding.
**What is the outlook for diagnostics and respiratory testing?** Non-respiratory diagnostics core growth was 7%, but respiratory revenue was about $350 million and fell year over year. Management plans for about $1.5 billion of respiratory revenue in 2026 and uses that as the 2027 starting point.

## Slides and investor documents

- [Presentation](https://investors.danaher.com/image/Q3+2026+Danaher+Earnings+Presentation.pdf) (Slide deck)

## Transcript

Machine-generated from https://www.youtube.com/watch?v=DCw_OQfcEPE


**Chelsea (Operator)** [0:00:00]
My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's third quarter 2026 earnings results conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star, then the number one on your telephone keypad. If you would like to withdraw your question, please press star 2.
I will now turn the call over to Ms. Rachel Vatnsdal, Vice President of Investor Relations. Ms. Bottenstahl, you may begin your conference.

**Rachel Vatnsdal (Investor Relations)** [0:00:41]
Good morning, everyone, and thanks for joining us on the call. With us today are Julie Sawyer Montgomery, our President and Chief Executive Officer, and Matt Guggeno, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, quarterly report on Form 10-Q, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call, and a note containing details of historical and anticipated future financial performance are all available on the Investors section of our website, www .danaher .com,
under the heading Quarterly Earnings. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events and Presentations and will remain archived until our next quarterly call. A dial-in replay of this call will also be available until November 4, 2026. During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. Our Form 10-2 and the supplemental materials I referenced describe additional factors that impacted year-over-year performance.
Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to results from continuing operations in the third quarter of 2026, and all references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals or are available only in certain markets. During the call, we will make forward-looking statements within the meaning of our federal security laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future.
These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements except as required by law. With that, I'd like to turn the call over to Julie.

**Julie Sawyer Montgomery (CEO)** [0:02:53]
Thank you, Rachel, and good morning, everyone.
Before we get into the quarter, I'd like to share my perspective on Danaher today and the opportunity ahead as I begin this next chapter as CEO. The opportunity for Danaher is straightforward to become the defining leader in life sciences and diagnostics, a company that unambiguously gained share, delivers sustainable, profitable growth, and helps our customers improve outcomes for patients around the world. The foundation we built at Danaher is strong. We operate leading businesses, foster deep customer relationships, and empower talented people, all enabled by the Danaher business system.
At the same time, growth over the past several years has not consistently reflected the full potential of our portfolio. We've navigated significant changes in our markets, but regardless of the environment, we hold ourselves to a higher standard. We see a meaningful opportunity to accelerate sustainable core revenue growth, gain share more consistently, and more fully translate the strength of our portfolio into differentiated performance. I'm confident in what we've built, and I'm energized by what I've seen across Dan or her these last few months.
Our focus now is strengthening execution and delivering on that potential. Recently, I had a conversation with one of our executives preparing for a customer meeting related to Alzheimer's disease. What started as a discussion about how one of our businesses could help address a particular part of that customer's challenge quickly expanded to cover the roles seven different operating companies could play across discovery, AI-enabled target selection, laboratory automation, process development, scale-up, and diagnostic testing. And when the challenge is Alzheimer's disease, speed matters, both to the scientists working to understand it and the families waiting for answers.
That conversation reinforced something important. Our customers don't think about their challenges through the lens of our organizational structure. They have a problem to solve and they want the best partnership and solutions we can bring them. I see this as critical to Danaher's next chapter as some of our greatest opportunities sit at the intersections of our businesses. We will preserve what makes our operating company structure advantaged, the customer intimacy, the accountability, while making it easier to bring the full power of Danaher to our customers.
Our foundation and the power of the Danaher business system have given us leadership positions across the life sciences and diagnostic markets and a unique role in helping accelerate the translation of scientific discovery into human impact. Our life science businesses enable discovery, our biotechnology businesses help turn those discoveries into scaled and accessible therapies, and our diagnostics businesses help guide treatment. Together, Danaher spans a broad path from experiment to patient with DBS adding speed and operating discipline at scale.
We call that innovation at the speed of life, helping close the distance between human need and the science that answers it. And as we enter this next chapter, we'll accelerate that ambition by focusing on four strategic priorities, commercial excellence, innovation, talent, and effective capital allocation. Each is important, but our most immediate opportunity is commercial execution. Danaher has successfully repositioned its portfolio with three platforms across the life sciences and diagnostics markets. With that portfolio transformation largely complete, our focus is shifting from reshaping the portfolio to delivering more growth from the businesses we own.
We will focus our leadership attention on exceptional commercial execution, enhancing our pursuit of unambiguous share gain across Danaher. We will drive consistency and rigor and commercial execution across our businesses. This means simplifying and strengthening our commercial processes and empowering our leaders to make more entrepreneurial decisions. We also have an opportunity to make it easier for our customers to take advantage of the full power of Danaher. Our operating companies have important brands and deep customer relationships. These will remain fundamental to how we compete, but Danaher has tremendous scale and breadth and we can do more to use that advantage.
That means making the broader strength of our portfolio and capabilities more accessible to customers. We've already taken practical steps to show up as a more connected Danaher. In diagnostics, for example, we are successfully deepening customer relationships by bringing leaders from across our businesses together with key customers to look across the portfolio, better understand their priorities, and identify where a more coordinated approach can create additional value. We do this by having our key diagnostics leaders in the same room at the same time with our key customers to understand their biggest pain points and where we can drive incremental value.
This approach has generated meaningful incremental revenue opportunities and is helping drive share gains across our diagnostics businesses. And as we bring more of DNA to our customers, we can also become more systematic about connecting capabilities across our businesses to solve more customer needs. Algevron and Cytiva's recent collaboration to deliver an end-to-end mRNA solution is a great example, helping streamline our customers' development processes while meaningfully accelerating timelines. Ultimately, our commercial strategy is straightforward. Execute better and more entrepreneurially, show up together as Danaher for our customers, and connect our capabilities where we can create greater value.
We will make it easier for customers to access the full strength of Danaher and look to us when trying to solve their most important challenges. Our second priority is delivering more innovation. Danaher is already at the forefront of innovation, but I believe strengthening our innovation capabilities represents one of our largest opportunities to accelerate long-term growth. Delivering on our brand promise, innovation, at the speed of life, means we will be deliberate and strategic about where we invest in R &D and ensure we appropriately allocate resources behind our best ideas.
That means more closely linking strategy in R &D investments, concentrating resources behind the highest potential initiatives, and working more closely across our businesses and external partners to move promising innovations faster. We will also fund transformational opportunities at the enterprise level when we believe Danaher has a clear right to win and larger investment can create meaningful competitive advantage. These decisions will require clear choices and greater enterprise-level conviction about where we can create the most value. Innovation cycles take time, but over the long term, we believe this more focused approach can support higher and more durable core revenue growth while turning more scientific discoveries into meaningful human impact.
And to me, this is the heart of innovation at the speed of life, helping promising science move faster towards the patients who need it. Our third priority is being the home and destination for exceptional talent. We believe our ability to attract and develop exceptional talent in scientific, AI, commercial and operating disciplines will increasingly set us apart from competitors. We also need to develop and deploy our people more intentionally against Danaher's highest priority growth and innovation opportunities.
Danaher has given me that kind of exposure in my own career, learning DBS and then applying it across commercial, R &D, and business leadership. I want us to continue to create exceptional opportunity for the next generation of leaders. As we evolve DBS for the AI era, I believe we can create an even more compelling place for the best talent in our industry. And our fourth priority is being more disciplined with our capital and resources. M &A and capital deployment have been essential drivers of Danaher's growth and will remain so.
We will maintain the robust investment criteria that has served us well for many decades while bringing strategic clarity and discipline to how we allocate capital and resources. We are focused on deepening our positions in attractive markets and identifying strategically compounding areas that build from the strengths we already have in our businesses. Our objective is to deliver high returns on our investments with greater consistency while positioning Danaher for sustainably differentiated and profitable growth. Across each of these priorities, there is a common idea.
We create more value by building a stronger, more connected company. That doesn't mean changing what makes our operating companies successful. It means preserving their customer intimacy and accountability while making it easier to share ideas, capabilities, talent, and resources across Danaher, and using our scale where it gives us an advantage. AI is one capability we believe can help us do just that. We believe the combination of AI and DBS will be an important competitive advantage. DBS gives us a common way to solve problems, improve processes, and scale what works across Danaher.
We believe that approach can help us bring AI solutions to life faster and more effectively than many. Over time, we believe AI can make DBS simpler and more powerful, while DBS can help us implement AI with the rigor and consistency that have long defined Danaher. We see opportunities for AI to strengthen commercial execution and innovation. For example, helping our teams identify opportunities earlier, improve sales funnel management, and dramatically reduce R &D timelines. AI can help simplify work and drive greater productivity.
But AI isn't only about making Dan or her better. It is also changing the needs of our customers and creating new opportunities across our portfolio. For example, we see growing demand for solutions that cut across our life sciences businesses that enable more automated and autonomous labs and workflows. We also see longer-term opportunities across our biotechnology and diagnostics platforms to make therapies more efficiently and make treatment decisions more precisely. This is why we are accelerating AI deployment across the enterprise and establishing AI partnerships.
Stepping back, we believe a more connected Danaher with a stronger focus on commercial excellence, innovation, and talent can be a stronger Danaher. We intend to bring the best of Danaher to our customers to better leverage our talent, platforms, and brand, and simplify how we operate so our teams can focus on the opportunities that matter most. Together, these actions can help us move faster and more fully realize the potential of our portfolio. So, I am incredibly excited about what lies ahead.
We are starting from a position of strength with meaningful room to deliver more. That will take time and we know credibility will be earned through results. Our focus now is making clear choices about where we invest and executing with greater speed and consistency. We believe that can accelerate profitable growth, drive share gains, and most importantly, help our customers improve outcomes for patients around the world. With that, let me turn to our third quarter results. Our third quarter came in ahead of our expectations on both the top and bottom line with biotechnology, life sciences, and diagnostics core revenue excluding respiratory revenue all growing mid-single digits or better.
Core revenue growth excluding respiratory revenue improved to 5.5 percent and we delivered a nearly 30% adjusted operating profit margin. These results reflect both improved in-market conditions and the benefit of strong commercial and operational execution across the portfolio. We're particularly encouraged by the improved momentum we saw across our businesses. Underlying demand across large pharma and biopharma remained robust, biotech activity continued to strengthen, and while academic demand remained below historic levels, demand improved sequentially. Meanwhile, clinical and applied in-markets remained healthy and continued to perform well.
Having spent considerable time with our teams over the past several weeks, I've seen firsthand the talent, innovation, and customer focus that make Danaher unique. Let me walk you through a few notable examples from across Danaher this quarter. During a recent visit to Cytiva's site in Uppsala, Sweden, I had the opportunity to spend time with the teams developing and manufacturing some of our industry-leading products. Seeing firsthand the depth of science and engineering behind these technologies reinforced my confidence in our competitive position.
I was particularly impressed by the process development team and how closely that team works side-by-side with customers to solve their most difficult challenges. That partnership has long been important in traditional monoclonal antibodies, and it It becomes even more valuable as our customers move towards more complex molecules and modalities. We're bringing innovation and process expertise to help customers solve those challenges. And importantly, we're seeing that differentiated approach help us win more specifications with customers. Next, we recently announced our first AI-powered autonomous lab.
Based at ADCAM, this lab brings together AI, robotics, and technologies from across our portfolio, including Cytiva, Beckman-Coulter Life Sciences, Gene Data, IDT, and Molecular Devices, to offer a connected design, make, and test workflow. By continuously learning from each experiment, the platform is designed to help researchers move from idea to validated reagent up to eight times faster while generating up to 10 times higher volume compared to existing models, helping accelerate scientific discovery while providing the rigorous quality and reproducibility required to advance AI-driven drug discovery.
Our partnership with NVIDIA announced last week will further advance this vision by connecting our instruments and workflows with NVIDIA's capabilities to help shape autonomous science for our customers. On the capital allocation front, Leica Biosystems closed the acquisition of StatLab in early Q4. StatLab strengthens Leica's value proposition by enabling a more complete pathology workflow while advancing our integrated delivery network strategy and helping clinicians diagnose cancer faster and more precisely. We're very pleased to welcome the StatLab team to Danaher.
Finally, Masimo, our other recent acquisition, continued to track ahead of our initial expectations and delivered another quarter of high single-digit revenue growth. Having spent time with the team just last week, the integration is progressing well across the business with a healthy funnel of cost savings and commercial synergy opportunities. The team has also continued to innovate at an impressive pace, recently receiving FDA clearance for a SmartSET platform that can help detect atrial fibrillation, a common heart rhythm disorder that often goes undetected and significantly increases the risk of stroke.
This technology can help patients earlier who may benefit from further medical evaluation and care. I want to congratulate the Masimo team for their sixth FDA clearance this year and for extending the value of their technology beyond monitoring to help detect important clinical conditions like atrial fibrillation. And with that, I'll turn the call over to Matt, who will walk you through our Q3 results and guidance in more detail.

**Matt Guggeno (CFO)** [0:21:42]
Thanks, Julie, and good morning, everyone. As Julie stated, we delivered a solid third quarter with better than expected growth, earnings, and cash flow.
Sales were $6.6 billion, and core growth, excluding respiratory revenue, was up 5.5%, and encouraging 100 basis points acceleration from the second quarter and a continuation of the improvement we've seen throughout the year. Respiratory revenue, while slightly better than expected, represented an approximately 250 basis point headwind in the quarter, resulting in core revenue growth of 3%. Geographically, core revenues in developed markets were flat. Western Europe grew mid-single digits, and North America was down low single digits, primarily driven by lower respiratory revenue.
Core revenues in high-growth markets increased approximately 10%, with healthy growth across all major regions. China was up high single digits, with growth in all three of our segments. Biotechnology and life sciences were supported by healthier funding, and investment levels and diagnostics continue to move beyond the most significant impacts of China's healthcare policy changes. Our gross profit margin for the third quarter was 58.5%. Our adjusted operating profit margin of 29 % was up 110 basis points and exceeded expectations, driven primarily by strong operational execution with a modest benefit from tariff refunds received during the quarter.
Adjusted diluted net earnings per common share of $2.11 were up approximately 11.5%. We generated $1.6 billion of free cash flow in the quarter and $4 billion in the first three quarters of the year, resulting in a year-to-date free cash flow to net income conversion ratio of 128%, further underwriting the differentiated quality of our earnings. Now, turning towards our business segments. Core revenue in our biotechnology segment increased 5%. Core revenue in discovery and medical decreased low single digits, with solid growth in protein research instrumentation more than offset by timing in lab consumables.
Core revenue in bioprocessing grew towards the upper end of mid-single digits, modestly better than our expectations. Consumables were up mid-single digits, led by upstream consumables, while equipment increased low single digits. orders grew mid-teens in the quarter with particular strength in both upstream consumables as well as residents. There is no change to our full-year expectation of mid-single-digit core revenue growth for bioprocessing. Demand trends remain healthy across the business, supported by strong commercial production activity and a robust pipeline of new programs.
These underlying market trends combined with Cytiva's differentiated portfolio, deep scientific expertise, and recent innovations reinforce our confidence in the business's ability to deliver sustainable, high-single-digit, long-term revenue growth while helping customers improve yields, increase manufacturing efficiency, and scale new therapies. Now, turning to our life sciences segment, core revenue increased 4.5%. Core revenue in Paul's applied filtration business increased mid-single digits, driven by continued robust growth in aerospace and microelectronics. Core revenue in our life sciences instruments businesses increased mid-single digits in the quarter.
SciEx led the way with strong demand from pharma and biopharma customers, a modest improvement in U .S. academic spending, and continued momentum for new products, such as Xenotof 8600. Beckman Coulter Life Sciences also delivered strong results, including an automation, where the team has seen increased demand for AI-enabled solutions and services. Core revenue in our life sciences consumables businesses collectively grew low single digits in the quarter, driven by continued momentum in IDT's MRD and next-generation sequencing product lines, while Abcam saw improved academic demand and solid traction from pharma and biopharma commercial initiatives.
Now moving to our diagnostic segment. Core revenue growth excluding respiratory revenue was up 7%. Respiratory revenue was an approximately 650 basis point headwind in the quarter, resulting in core revenue growth of 50 basis points. Core revenue in our clinical diagnostics businesses increased mid-single digits in the quarter. We saw notable performance at Leica Biosystems with particular strong momentum in digital pathology as well as advanced staining. Beckman Coulter Diagnostics also delivered its highest core growth quarter in more than two years.
The traction we saw from new product introductions, including the DXi9000, together with easing China policy-related headwinds, reinforces our confidence in Beckman's competitive position and ability to accelerate their growth trajectory. In molecular diagnostics, core revenue in Cepheid's non-respiratory business increased low double digits, led by growth in Group A strep, virology, and sexual health assays. Respiratory revenue is approximately $350 million in the third quarter, down year-over-year, due primarily to lower global infection rates, but modestly ahead of our expectations as we saw customers purchase ahead of the upcoming respiratory season.
Now let's turn to our fourth quarter in full year 2026 outlook and give you an initial perspective on how we're thinking about 2027. In the fourth quarter, we expect core revenue growth, excluding respiratory revenue, to be in the 4 % to 5 % range. We expect respiratory revenue to be an approximately 150 basis point headwind. Additionally, we expect a fourth quarter adjusted operating profit margin of approximately 29.5%. For the full year 2026, we are increasing our full-year adjusted diluted net EPS guidance to $8.57 to $8.62 versus our prior range of $8.45 to $8.60.
This reflects the benefit of our third quarter outperformance and represents double-digit year-over-year EPS growth. Now turning to 2027. While it's still too early to provide a formal outlook, we want to give you some perspective on how we're thinking about core growth next year. We're encouraged by the improvement in the end markets and the growth we've delivered throughout 2026. Excluding respiratory revenue, core revenue growth has averaged 4 % to 5 % over the past several quarters.
So as we look to 2027, we think that 4 % to 5 % core revenue growth, excluding respiratory revenue, is the right starting point as we sit today. We'll provide a more quantitative and detailed guidance outlook in January, but hopefully this gives you a helpful starting point for how we're thinking about next year. With that, I'll turn the call back over to Julie.

**Julie Sawyer Montgomery (CEO)** [0:28:56]
Thanks, Matt. So to wrap up, we're pleased to deliver better than expected third quarter results and encouraged by the improving growth trends we saw across the business.
As I reflect on my first few weeks as CEO, the time I spent with our teams and customers has only strengthened my conviction and the solid foundation Danaher has built. My focus now is simple, create more value for customers, accelerate innovation, attract and develop great talent, and deploy capital in ways that strengthens Danaher for the long term. These priorities are designed to drive faster and more durable core growth, deliver unambiguous share gains, and more fully translate the strength of our portfolio into differentiated performance.
While realizing the full potential of these opportunities will take time, I am confident that with DBS as our foundation, we're uniquely positioned to turn those opportunities into results for our customers and the patients they serve, our associates, and our shareholders. I'm excited about what we can accomplish together and the results we can deliver as we continue building an even stronger Danaher. So with that, I'll turn the call back over to Rachel.

**Rachel Vatnsdal (Investor Relations)** [0:30:07]
Thanks, Julie. That concludes our formal comments.
We're now ready for questions.

**Chelsea (Operator)** [0:30:12]
Thank you, Rachel. At this time, if you would like to ask a question, please press star one on your keypad. To leave the queue at any time, please press star two. We ask that you please limit yourself to one question and one follow-up. Once again, that is star one to ask a question. And our first question will come from Doug Schinkle with UBS. Please go ahead.

**Doug Schinkle (UBS)** [0:30:39]
Hi, good morning. Thank you for taking my questions.
And Julie, welcome to the call. So as the new CEO, you're new to the role, but as we all know, you are certainly not new to Danaher. So recognizing that and also that this has been a challenging period for the company, but also that Danaher has a legacy of operational excellence and solid capital deployment, how are you balancing the legacy of a company that has business school case studies written about its strategy and execution versus the opportunity and need to make change?
Essentially, as you sit here today, what's foundational and how do you think about evolving the playbook?

**Julie Sawyer Montgomery (CEO)** [0:31:23]
Thank you, and thank you for the thoughtful question. Danaher is a great company and one I am incredibly proud to lead. And we have a great heritage with HBS case studies written about us, and I know exactly what you are referring to as I read that case study when I decided to join Danaher nine years ago. We also have truly unique differentiators that continue to serve us well today.
Exceptional talent, a great portfolio, and a continuous improvement culture supported by a business system that is unparalleled. At the same time, as I said in my prepared remarks, we have an opportunity to grow at a higher rate than we have in recent years. And when I talk to our teams, I say that unambiguous share gain is our true report card. So I want to preserve what makes us great, but also ensure we are focused on the most important priorities for who we are today.
So let me break that down a bit. You heard me talk about becoming a more connected Danaher. When that Harvard case study was written, our businesses were lower growth markets and our customers typically bought from a single operating company. We are in a very different situation today. Higher growth scientific markets with the same customers buying across three, six, 12 operating companies. So we will keep the advantages of our operating company structure in place. I think of that as the accountability, the customer and technical intimacy, and the unique development opportunities for our people.
But we will also work in a more connected way that makes it easier for customers to access the full power of Danaher. You know, I still talk to customers who are surprised to learn that company XYZ is part of Danaher, and yet we are a strategic partner to those customers. These customers are inevitably interested in a broader conversation that can lead to a higher share of wallet for us and better solutions for the customer. And that same thinking, ensuring we are focused on what matters most for the company we are today, extends to our other priorities.
You heard me say we will focus more on commercial excellence. Now that we are in a growthier market, more leadership focus on commercial prowess leads to more value creation. I also spoke about strategy-led innovation. This is important because our markets today are fueled by scientific discovery. And as a result, we need to know where the puck is going and to make focused, higher impact investments. and talent. For this age and these markets, we need to develop and attract the best AI, science, technology, and operating talent to innovate at the speed of life.
And we will want to continue to focus on capital allocation while ensuring we do so in strategically compounding ways to help the flywheel of our businesses turn better and faster. So what you hear me saying is I don't view these priorities as a generic playbook, but as what best enables us to become that defining leader now that we are a fully scaled life sciences and diagnostics company.

**Doug Schinkle (UBS)** [0:35:02]
Thanks for that, Julie. One follow-up on your prepared remarks from earlier on the call.
You outlined several priorities. What's the biggest one that you expect to have the greatest impact over the near term, say over the next 12 to 18 months? And what operating or financial metrics should investors use to assess progress pursuant to that top priority?

**Julie Sawyer Montgomery (CEO)** [0:35:29]
Sure. You know, step one is really prioritizing and aligning our teams around accelerated profitable growth and unambiguous share gain as the report card. And that's what our investors should be looking for. And that leads to a clear near-term opportunity to further drive commercial excellence across the enterprise.
This means being super clear on simple but powerful expectations for our sales team and what leaders will drive and inspect. And frankly, this is where DBS creates a real advantage for us. What will then further accelerate this is when we consistently show up as a more connected Danaher. There are pockets across the business where this is working extremely well. I mentioned we've seen a lot of success with this in diagnostics, where we started to speak to customers as diagnostic solutions in addition to individual operating companies, and this has led to much more senior and strategic dialogues and value propositions that have created several hundred millions of dollars of opportunity in a short time.
We are also seeing this in our life sciences approach to the new tech bios, and we have approached these AI native drug development companies this way from the start, and I really like the traction we are seeing. And one of the things I've been pleased to learn over the course of my transition to CEO is that when I talk to customers across all three of our platforms, terms, they want to see more of this from us.
So, you know, these changes will take some time, but our report card is higher core growth, profitable core growth, and unambiguous share gain.

**Chelsea (Operator)** [0:37:25]
Our next question will come from Vijay Kumar with Evercore ISI. Please go ahead.

**Vijay Kumar (Evercore ISI)** [0:37:31]
Hi guys, good morning and thank you for taking my question and Julie, congratulations to you. I guess my first question, Matt, I think you made some helpful comments here on the fiscal 27 framework. I'm curious when I look at your bio processing segments, came in quite solid here in 3Q and you have a few moon pieces in your 27.
The instrument orders have been quite solid here year-to-date. You could see some activity from onshoring. You do have a catch-up from this order push-out and consumables. So, I'm curious, should bioprocessing be pushing very high singles, low double digits, you know, when you think about fiscal 27?

**Matt Guggeno (CFO)** [0:38:18]
Yeah, Vijay, thanks for the question here. So, I think just to start with bioprocessing here for 26 and how we feel like we're going to finish the year.
So, no change to our full-year expectations for 2026 for bioprocessing, mid-single-digit core growth. We saw Q3 was actually a bit better than we expected the upper end of that mid-single-digit range. And from an orders perspective, they remain strong. Mid-teens order growth that was led by upstream consumables as well as resins. So given order trends and those order trends that we're seeing, we'd expect to see bioprocessing growth rates continue to improve in 2027.
We gave that overall Danaher outlook of 4 % to 5 % core growth extra respiratory. As we want to get through our planning processes and as we'll do with the rest of our businesses, we want to see how Q4 shapes up here before we provide more formal guidance, whether it's around bioprocessing or the other segments here. But all in, good to see the order trajectory, view bioprocessing long-term as a high single-digit growth business and encouraged by what we're seeing.

**Julie Sawyer Montgomery (CEO)** [0:39:29]
And, you know, VG, I can add a little bit of color here because, as you would imagine, this is a place where I've spent quite a bit of time recently both with a team and with customers. And, you know, my conclusion is we have a differentiated portfolio with the most comprehensive offering and bio processing. And this really positions us to win with virtually any customer across nearly every step of the workflow. You know, we like the secular drivers.
There's a record number of monoclonal antibodies coming to market, the acceleration of biosimilars, and newer modalities like the antibody drug conjugate, cell therapy, the bi-tri-specifics are adding to the volume, and of course, the reshoring opportunity. And as I meet with customers, it is clear they value us as a critical partner and not just a supplier. They bring to us their most critical problems and we are very good at solving them. So all in, very confident that bioprocessing is a high single digit business here over the long term, as Matt has said.

**Vijay Kumar (Evercore ISI)** [0:40:40]
That's helpful, Julie, and maybe one for you on capital deployment. Love to hear your views on capital deployment. You know, you come from diagnostics. We've seen a couple of acquisitions within the segment. How are you thinking of M &A opportunities and areas of interest for Danaher? And the reason I ask on areas of interest is, I know Masimo, is that kind of signaling a more a medtech tilt, if you will, or how are you thinking of areas of priorities?

**Julie Sawyer Montgomery (CEO)** [0:41:10]
Yeah, thanks Vijay. M &A remains our bias for capital allocation, as we think it's the best way to compound returns over the long term. And we're going to continue to look for strategically compounding M &A. And of course, we'll keep robust investment criteria that has served us well for decades. And we see Masimo and just recently here StatLab as good examples of this. And I see opportunities to strengthen all three of our platforms, both organically and inorganically through M &A.
You know, you talk about Masimo. I actually don't see that as a med tech M &A play. I see it as a continuous diagnostic that is strategically compounding with our diagnostics business. We already see the commercial synergies at work and we're able to have scientific conversations around how the combination of continuous monitoring and biomarkers can lead to better outcomes for patients. So just another example of something that we view as strategically compounding. There's certainly no bias here to MedTech.

**Chelsea (Operator)** [0:42:39]
Our next question comes from Tycho Peterson with Jeffries. Please go ahead.

**Tycho Peterson (Jefferies)** [0:42:42]
Hey, thanks. Matt, I want to stress test the assumptions you kind of put out for next year, the 4 % to 5%. I have a lot of people asking why you're not kind of accelerating here. I appreciate your comments on bioproduction, you know, a minute ago. You had the order of residue delays, obviously, in biotech. That should come through. You don't have the China VBP headwinds.
You've got recovering biotech, academic picking up a bit. So, you know, why on earth would X respiratory be the same? I think, you know, you kind of alluded to the fact you just want to see how 4Q shapes up and 4 to 5 is maybe a floor. but maybe get us comfortable there's something that you're not baking in that's getting worse.

**Julie Sawyer Montgomery (CEO)** [0:43:22]
Hey Tycho, this is Julie of course. So you know as Matt discussed, we've delivered core growth ex-respiratory in the four to 5% range the last few quarters and so we think that's a reasonable starting point for 2027 based on the current in market conditions.
You know, I'm only a few weeks into the CEO role, but the time I spent with our teams and customers has certainly reinforced my confidence in our positioning and the improving in markets. But we really want to work through our typical planning process here that we go through in Q4, and then we will provide you a more quantitative outlook in January.

**Tycho Peterson (Jefferies)** [0:44:01]
Okay. And then follow up, Julie, on diagnostics. You know, on respiratory, you guys did a good job walking down expectations for respiratory this year.
You know, understand weak flu season overall, but why another $100 million cut when the data is starting to turn here? 3Q came in above. Is that conservatism, or, you know, are you seeing something in the data that leads to the cut here? And then as we think about 27, we have a lot of questions about the endemic rate. Is $1.5 billion the right way to think about it, or how do you think about the new endemic rate?

**Julie Sawyer Montgomery (CEO)** [0:44:31]
Yeah, Teiko, so we are planning for $1.5 billion in respiratory this year, and I think that's also the right starting point for next year as well. And really what I want to do here is to create an expectation for a down-the-middle-of-the-road flu season. And as you know, there is variability in flu seasons year-to-year, season-to-season, and And yes, that can create a couple $100 million of bookends around that number.
What we're seeing in Q4, sounds like you follow it, as you know, you know, we've been lower than last year, almost every week this year. There's been just this little bit of a tick up recently, but we think that's way too early to call, and you really can't say much about the flu season until you see that ILI curve tick above 3%, and then you're sort of officially in the season, and that doesn't typically happen to late November, early December after everyone's enjoyed some Thanksgiving turkey.
So at this point, we think it's prudent just to call what we now see as that more typical down-the-road flu season.

**Chelsea (Operator)** [0:45:52]
Our next question will come from Jack Meehan with Opera Research. Please go ahead.

**Jack Meehan (Seaport Research)** [0:45:58]
Thank you and good morning. Julie, I wanted to pull you a little bit more on your views on AI. I appreciate all the emphasis that got in your opening remarks. Just would love to hear from you now that you're in the CEO seat, just how you think about the implications for Danaher and any updates you can share around how you're deploying it with DBS?

**Julie Sawyer Montgomery (CEO)** [0:46:26]
Sure, yeah. So thanks for the question. We see AI-driven Doug discovery as a significant long-term opportunity for us and in my view it will clearly make the world a healthier place, which is incredibly exciting. And we believe that Danaher is uniquely positioned to help shape this market frankly because we have all of the building blocks you know our breadth as Dan or her has always been a competitive advantage for us but even more so I believe that will be the case in the age of AI so we have all five pieces of the equation needed we have the instruments Think about molecular devices, SIACS, Leica Micro.
We have the consumables, IDT, ADCAM. We have the automation, BEC-LS, our Automata partnership. We have the software and gene data and IDBS. And lastly, we have the scale that makes us a priority for the frontier labs. So, while it's not material today, we have started to see a modest benefit to our orders and revenue. And frankly, it's at the forefront of every customer conversation I have in life science. And it's our ambition to be a leading partner as our customers adopt AI.
And we believe the full power of our platforms positions us exceptionally well to use AI to help accelerate scientific discovery. And of course, we're also using it internally. You know, I think that DBS and AI have a really natural synergy. As a company, culturally, we excel at thinking about processes and identifying the critical path in that process. And that enables us to focus AI on where it's going to create the most value for us. And then we have the ability to follow that up with strong KPIs in daily management.
I think that's going to be a really powerful combination as we roll out AI here.

**Jack Meehan (Seaport Research)** [0:48:54]
Excellent. And then maybe just would be great to double-click a little bit in some of the announcements that have come out related to AI, whether it's with NVIDIA or the Autonomous Lab Lab Cam. Just like what's the bigger strategy here? Is there a potential to broaden some of these things across the organization?

**Julie Sawyer Montgomery (CEO)** [0:49:15]
Sure. Yeah, we were very excited to announce our plans for our first AI-powered autonomous lab, and that brings together AI, robotics, and technologies from across Danaher into an integrated continuous learning workflow.
So the simplest way to think about this is that we are working to connect AI to the physical experiment. Lots of organizations can ask AI what their next experiment should be. I still remember the first time I saw that work. It was amazing. But we can do more. Our autonomous lab has AI design the experiment, and then our technology makes the reagents and tests those reagents, and then the results feed the next experiment. So this creates a full design, make, test, closed loop, which is leading to 8x faster discovery of reagents and a 10x productivity enhancement.
And the autonomous lab, that's something that we are starting here within Danaher. Danaher. We've gotten a lot of customer interest in it and customers even going to see that at work at our Abcam facility. So we want to demonstrate that we can do it in Danaher and then work with our customers. The NVIDIA collaboration is also something we recently we announced, and there we're collaborating with NVIDIA to help accelerate the adoption of AI and scientific research and drug discovery.
And the goal is to combine our instruments, automation, and software with NVIDIA's AI and advanced computing technologies. So this means more intelligent instruments and automated lab workflows via edge computing, And it means exploring AI models and digital twins to simulate and optimize experiments before running them. So a lot of work underway here with NVIDIA, and we're excited to build on the collaboration over time. And frankly, we're also working with Anthropic, and you probably saw some of the model hardware standards that were part of their research preview program.
And this is about making our instruments easier to connect to other agents and other instruments. So we think that's an important part of utilizing the value of our breadth.

**Chelsea (Operator)** [0:51:56]
Our next question will come from Scott Davis with Milius Research. Please go ahead.

**Scott Davis (Melius Research)** [0:52:03]
Hey, good morning, Julie and Matt and Rachel. Yeah. Julie, I wanted to dig into this commercial execution just a little bit because you're – it sounds easy and I'm sure it's incredibly difficult. So what do you – what's the first step?
Do you have to change compensation schemes? Do you have to change out people? I mean, what – how do you really drive – I mean, I'm sure Reiner cared about commercial execution. So how do you really drive change at the pace that you want to drive? Do you have to change, I think, some processes and structure around that to get there?

**Julie Sawyer Montgomery (CEO)** [0:52:43]
Yeah, you know, thanks for the thoughtful question. You know, there's a couple of steps here.
You know, one, in terms of commercial execution, I am a fanatic on what we referred to at Dan or her as the commercial standard condition. And this is really taking DBS down to a very simple place and being extremely clear about what we expect from our sales teams. And we really doubled down on that in diagnostics and the other platforms have taken that as some inspiration and have been holding workshops to make sure that we are doing the same.
And one of the things that's interesting is we're even experimenting with how AI can make how we coach and inspect our sales results even simpler, which I think is a really exciting opportunity for us. And then when it comes to this more connected selling process, you know, it's both easy and difficult, and I think that it's easy when you kind of get the incentives right and you touched on that. When we first started doing this in diagnostics, one of our rules is when we have a solutions group team go out and talk to customers, no one's incentives are ever hurt.
And frankly, the opportunity is clear enough here that I'm happy to double pay on incentives because as you're using the power of Dan or her to increase our share of wallet with customers, there's significant win-win opportunities there to go after.

**Scott Davis (Melius Research)** [0:54:32]
Thanks for the question. And no thanks for the answer and and high integrity of that answer. But I'm going to ask the same exact question around M &A because clearly there's, you know, Danner's 50-year history, there's a long history of very successful M &A and there's been a few stinkers in there obviously that have impacted your portfolio of late.
But how do you change, I mean, what do you feel the need to change the process? And again, I was asking kind of the same way process or the people do you change kind of how you work the funnel I mean how do you how do you drive to that lower risk higher consistency you know higher return kind of kind of mandate and still put capital to work because I've seen other companies go through stages and they kind of freeze you know they become afraid to do deals because they're afraid to make a mistake.
So how do you keep that flywheel moving so that you're putting capital to work but increase your hit rate from here?

**Julie Sawyer Montgomery (CEO)** [0:55:41]
Yeah, no, thank you for the question. We certainly don't want to freeze. Capital allocation remains a priority for us. And frankly, we have great processes and great teams for M &A. So you mentioned some and, you know, that haven't performed as well in the recent past. And I think as a company, we have learned from that, but our focus is really just ensuring that we're doing strategically compounding M &A with a robust return profile.
And if you look at our recent deals, obviously it's early days, but I think that they will be strong returns for us and strategically compounding. Thank you.

**Chelsea (Operator)** [0:56:26]
Our next question will come from Casey Woodring with JPMorgan. Please go ahead.

**Casey Woodring (JPMorgan)** [0:56:31]
Great. Thank you for taking my questions. And, Julie, looking forward to working with you. Maybe a follow-up to an earlier question, but just on Masimo, you talked a little bit about how you view the business fitting into Danaher, and you obviously led that deal as head of diagnostics.
But maybe can you just walk through the current trends you're seeing in that business and how we should think about Masimo contribution next year?

**Julie Sawyer Montgomery (CEO)** [0:57:02]
Yeah, thank you for the question. Masimo is off to a great start. They delivered high single digits here in Q3, their first full quarter as part of Danaher and year to date as well. And, you know, I was just with the team last week. The integration is progressing extremely well. They've already completed in sustainment for over 10 Kaizens with more planned along the way.
And frankly, it's just tremendously rewarding to work with that team and see them get excited about DBS, how the lean thinking can support, you know, a better cost position, better on-time delivery for the customers. And then also, you know, we have a healthy funnel of the commercial synergies that we were anticipating. And, you know, in true Danaher fashion, we will also learn from Masimo. We're extremely impressed by their rate of innovation and some of their commercial techniques as well.
And that's always been part of what makes Danaher stronger.

**Casey Woodring (JPMorgan)** [0:58:18]
Understood. That's helpful. And then maybe as a follow-up, you called out mid-teens order growth in bioprocessing. If you could maybe just double-click on the equipment piece of that order growth, maybe parse out how much pent-up demand you're seeing over the last several quarters, and then would also be curious to hear on reshoring as well, kind of what you're seeing from an order perspective there and how reshoring could potentially contribute to growth in 27.
Thank you.

**Matt Guggeno (CFO)** [0:58:45]
Sure, Casey. I'll take the order growth part of the question, and then kick it over to Julie for reshoring. So another quarter of mid-teens order growth overall in bioprocessing that was led by upstream consumables as well as resins, encouraged by those trends, continued to build backlog here. And also when you think about equipment versus consumable orders year to date, both up nicely with those equipment orders continuing in that strong double-digit range. So really supportive of those improving on end market and underlying trends in the business.

**Julie Sawyer Montgomery (CEO)** [0:59:18]
Yes, and Casey, on reshoring, I mean, reshoring is playing out largely as we expected. We're seeing some brownfield activity today, and that has a modest impact to our order book at the moment. Those larger greenfield projects are still in the planning phases. The funnel and quoting activity is beginning to pick up, but we see that as more of a 2028 plus event in terms of when it starts to hit the P &L. We do think this is a strong opportunity ultimately for the business, and it could be a billion-dollar market opportunity in the U .S., but as I said, we'll expect it to play out across several years, mostly starting in 2028.

**Chelsea (Operator)** [1:00:12]
Our last question will come from Evie Kozlowski with Goldman Sachs. Please go ahead.

**Evie Kozlowski (Goldman Sachs)** [1:00:16]
Great. Thank you for squeezing me in. And, Julie, congrats on the new role. So within life sciences, maybe walk through the key end markets of where we are in the recovery within academic and then biotech, but maybe specifically within emerging biotech, and then also within industrial and semis. And then what are you hearing from customers in terms of where they are with spending versus kind of where we still have room in the recovery and any areas that investors should look for for potential acceleration and leverage for upside into next year?

**Julie Sawyer Montgomery (CEO)** [1:00:47]
Great. Thank you, Evie, for the question. So, you know, you saw here in Q3, we grew 4.5 % and, you know, finished above our expectations,! driven by the improving in-markets and the traction and some recent commercial initiatives, as well as some new product launches. And frankly, this is the third quarter in a row where life sciences has beat our internal expectations. The in-markets continue to steadily improve. Large pharma and biopharma remained robust. Biotech funding is reading through.
Academic demand is still below historic levels, but improved modestly sequentially. And we saw continued strength in clinical and applied markets, including in micro-E at EPPOL. And, you know, our customers, they are really interested, and we're starting to see some of that early demand for the AI-driven workflow solutions. And that's first starting to show up in automation, Beckman Life Sciences. And as I mentioned, I think we're very well positioned here in AI. Customers like the breadth of our portfolio, and we will turn that into a value proposition for them that's around ease of integration through common standards across the instruments.

**Chelsea (Operator)** [1:02:25]
We've now reached our allotted time for questions, and I'd like to turn the call back over to Rachel for any additional or closing remarks.

**Rachel Vatnsdal (Investor Relations)** [1:02:33]
Perfect. Thank you, operator. Thank you, everyone, for joining us today, this morning. We'll be around the rest of the day and the week for follow-ups if any of you have questions.

**Chelsea (Operator)** [1:02:43]
Thank you, ladies and gentlemen. This brings us to the end of today's meeting. We appreciate your time and participation, and you may now disconnect.
